Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Open-Label, Phase 2 Study of Blinatumomab after First-Line Rituximab-Chemotherapy in Adults with Newly Diagnosed, High-Risk Diffuse Large B-Cell Lymphoma

Deborah A. Katz, MD, Michael P. Chu, Kevin A. David, MD, Catherine Thieblemont, MD PhD, Nicholas J. Morley, Sharif S. Khan, Yuqi Chen, James Kalabus, Joan Morris, Abraham Anderson, Ariel A. Avilion, Eva González-Barca, MD PhD

Blood (2019) 134 (Supplement_1): 4077.

https://doi.org/10.1182/blood-2019-121708

Published: 2019

Journal Articles

Adolescent and Young Adult Leukemia and Lymphoma Care Delivery in the Community: Metrics and Outcomes of a Community-Based, Immersive AYA Program

Hal E Crosswell, MD, Fahd Quddus, MD, Sharif S. Khan, MD

Blood (2018) 132 (Supplement 1): 4733.

https://doi.org/10.1182/blood-2018-99-111526

Published: 2018

Journal Articles

A Phase 2 Study of Actinium-225 ( 225 Ac)-Lintuzumab in Older Patients with Untreated Acute Myeloid Leukemia (AML) - Interim Analysis of 1.5 µci/Kg/Dose

Ehab L. Atallah, MD, Johnnie J. Orozco, MD PhD, Michael Craig, MD, Moshe Yair Levy, MD, Laura E. Finn, MD, Sharif S. Khan, MD, Alexander E. Perl, MD, Jae H. Park, MD, Gail J. Roboz, MD, William Tse, MD, Kebede H. Begna, MD, Raya Mawad, MD, David A. Rizzieri, MD, Mark S. Berger, MD, Joseph G. Jurcic, MD

Blood (2018) 132 (Supplement 1): 1457.

https://doi.org/10.1182/blood-2018-99-111951

Published: 2018

Journal Articles

Efficacy of 90Y-Ibritumomab Tiuxetan in the Older Population with Non-Hodgkin Lymphoma Pre-Treated with Rituximab-Based Regimens: A Single-Institution Experience

Vaibhav Agrawal, MD MBA, Smelser T. Diane, PhD, Jose I. Castillo, MD, Kelly Raup, RN, Girton D. Treanna, RN, Scotty R. Collins, MD, James O. Brady, MD, Sharif S. Khan, MD

Blood (2017) 130 (Supplement 1): 4066.

https://doi.org/10.1182/blood.V130.Suppl_1.4066.4066

Published: 2017

Journal Articles

Effect of the CEP72 Genotype and CYP3A5-Mediated Metabolism in Predicting Vincristine-Associated Peripheral Neuropathy

Vaibhav Agrawal, MD, M.B.A., Diane T. Smelser, PhD, David J. Carey, PhD, Joseph J. Vadakara, MD, Sharif S. Khan, MD

Blood (2016) 128 (22): 5963.

https://doi.org/10.1182/blood.V128.22.5963.5963

Published: 2016

NARROW

Open-Label, Phase 2 Study of Blinatumomab after First-Line Rituximab-Chemotherapy in Adults with Newly Diagnosed, High-Risk Diffuse Large B-Cell Lymphoma

Adolescent and Young Adult Leukemia and Lymphoma Care Delivery in the Community: Metrics and Outcomes of a Community-Based, Immersive AYA Program

A Phase 2 Study of Actinium-225 ( 225 Ac)-Lintuzumab in Older Patients with Untreated Acute Myeloid Leukemia (AML) - Interim Analysis of 1.5 µci/Kg/Dose

Efficacy of 90Y-Ibritumomab Tiuxetan in the Older Population with Non-Hodgkin Lymphoma Pre-Treated with Rituximab-Based Regimens: A Single-Institution Experience

Effect of the CEP72 Genotype and CYP3A5-Mediated Metabolism in Predicting Vincristine-Associated Peripheral Neuropathy

Email alerts

ASH Publications

American Society of Hematology

Open-Label, Phase 2 Study of Blinatumomab after First-Line Rituximab-Chemotherapy in Adults with Newly Diagnosed, High-Risk Diffuse Large B-Cell Lymphoma

Adolescent and Young Adult Leukemia and Lymphoma Care Delivery in the Community: Metrics and Outcomes of a Community-Based, Immersive AYA Program

A Phase 2 Study of Actinium-225 ( 225 Ac)-Lintuzumab in Older Patients with Untreated Acute Myeloid Leukemia (AML) - Interim Analysis of 1.5 µci/Kg/Dose

Efficacy of 90Y-Ibritumomab Tiuxetan in the Older Population with Non-Hodgkin Lymphoma Pre-Treated with Rituximab-Based Regimens: A Single-Institution Experience

Effect of the CEP72 Genotype and CYP3A5-Mediated Metabolism in Predicting Vincristine-Associated Peripheral Neuropathy

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only